Compare · PACB vs WAT
PACB vs WAT
Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PACB and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $40.72B, about 86.2x PACB ($472.5M).
- PACB has been more active in the news (7 items in the past 4 weeks vs 6 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 24 for PACB).
- Company
- Pacific Biosciences of California Inc.
- Waters Corporation
- Price
- -
- -
- Market cap
- $472.5M
- $40.72B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2010
- 1995
- News (4w)
- 7
- 6
- Recent ratings
- 24
- 25
Pacific Biosciences of California Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest PACB
- Officer Van Oene Mark sold $30,409 worth of shares (26,911 units at $1.13), decreasing direct ownership by 0.98% to 2,705,853 units (SEC Form 4) to satisfy withholding obligation
- Officer Van Oene Mark was granted 489,130 shares, increasing direct ownership by 22% to 2,732,764 units (SEC Form 4)
- SEC Form 10-Q filed by Pacific Biosciences of California Inc.
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- PacBio Appoints Mark Van Oene as President and Chief Executive Officer
- PacBio Announces Second Quarter 2026 Financial Results
- PacBio Announces Faster Runs, Up to 50% More HiFi Data, and New Compliance Controls for the Vega system
- PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
- PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
- Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update
Latest WAT
- SEC Form 8-K filed by Waters Corporation
- SEC Form 10-Q filed by Waters Corporation
- Director Kuebler Christopher A sold $1,442,930 worth of shares (3,626 units at $397.94) and exercised 3,626 shares at a strike of $136.43 (SEC Form 4)
- Waters upgraded by TD Cowen with a new price target
- Waters Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results
- Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)